I'm sure there are people who would say that European regulators are being permissive to the point that they're harming the health of patients. A lot of women in the US could have benefited from thalidomide while it was being used in Europe, but the FDA was too cautious to allow it.
People will benefit from those extra 11 hours, but they'll also be hurt by the lower accuracy. It's completely reasonable for different people to weigh these costs and benefits differently.
> People will benefit from those extra 11 hours, but they'll also be hurt by the lower accuracy
11 hours without a CGM is a much greater risk than marginally lower accuracy. As a potential user of this system I've been unable to locate research to convince me otherwise.
People will benefit from those extra 11 hours, but they'll also be hurt by the lower accuracy. It's completely reasonable for different people to weigh these costs and benefits differently.